Caplin Point Laboratories Limited has informed the Exchange regarding a press release dated October 23, 2025, titled "CAPLIN STERILES GETS USFDA APPROVAL FOR NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE INJECTION, INFUSION BAGS".
CAPLIPOINT · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Caplin Point Laboratories' subsidiary Caplin Steriles has received USFDA approval for Nicardipine Hydrochloride in 0.9% Sodium Chloride Injection, packaged in infusion bags. Nicardipine Hydrochloride is a calcium channel blocker used to treat high blood pressure (hypertension). This approval allows the company to manufacture and market this injectable product in the US market. The approval strengthens Caplin Steriles' injectable portfolio for the US market, which is a key revenue driver for the company.
Positive for the stock — USFDA approvals expand the addressable US market and can boost injectable segment revenues, though actual financial impact depends on launch timeline and market share capture.